GSK plc 6-K, filed Feb 14, 2023
GSK plc (GSK)
6-K
2023-02-14
For: 2023-02-14
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on February 14, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GSK plc (the 'Company')
2023 Performance Share Plan Award and 2023 Performance
Measures
2023 Performance Share Plan Award
On 9 February 2023, the Company granted conditional share awards to
the Persons Discharging Managerial Responsibilities ('PDMRs') and
their Persons Closely Associated ('PCAs') listed below under the
GlaxoSmithKline 2017 Performance Share Plan ('the Plan'). The Plan
was approved by shareholders on 4 May 2017 and allows a
performance-related opportunity in the form of conditional awards
to be granted to senior executives in the Group, including the
Executive Directors and other PDMRs.
Under the terms of the Plan, conditional awards are granted over a
specific number of Ordinary Shares or American Depositary Shares
('ADSs'), and the percentage of awards that ultimately vests is
dependent on the level of achievement against performance targets
set by the Remuneration Committee.
2023 Performance Measures
In accordance with the Remuneration Policy and company growth
focus, the awards will be based on the following five
measures:
|
Performance Measure
|
Proportion of
each award
|
|
Relative
Total Shareholder Return (TSR)
|
30%
|
|
GSK
Total Sales
|
20%
|
|
GSK
Profit
|
20%
|
|
Pipeline
Progress
|
20%
|
|
ESG:
Environment
|
10%
|
The performance period for the awards is the three financial years
from 1 January 2023 to 31 December 2025.
Relative TSR measure
This measure compares the TSR of the Company's Ordinary Shares over
the performance period with the TSR of the shares of nine (9) other
global pharmaceutical companies (i.e. a comparator group of ten
(10) companies including the Company). This TSR comparator group
remains unchanged. The companies in the TSR comparator group are
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson &
Johnson, Merck & Co, Novartis, Pfizer, Roche Holdings, Sanofi
and GSK.
In a group of 10 companies, the median (position 5.5) falls between
two companies. The vesting schedule for the 2023 awards is as
follows:
|
Ranking position
|
Vesting Schedule
|
|
1st,
2nd or 3rd
|
100%
|
|
4th
|
70%
|
|
5th
|
40%
|
|
Median
(Threshold vesting)
|
25%
|
|
6th or
below
|
0%
|
GSK Total Sales & Profit measures
The Total Sales and Profit measures recognise the importance of the
commercial ambitions in our Investor Update ('IU') and the
Committee has set targets that reinforce those commitments.
The targets for GSK Total Sales and Profit measures are of
their nature commercially sensitive at the time of grant. At the
end of the performance period we will provide full disclosure of
what has been achieved. Reflecting our growth agenda the Threshold
for vesting for both measures is now 99% of target.
Both the Total Sales and Profit measures in the 2023 award will
vest as follows:
|
|
Performance vs Target
|
Proportion Vesting
|
|
Below
Threshold
|
<99%
of Target
|
Nil
|
|
Threshold
|
99% of
Target
|
25%
|
|
Target
|
100% of
Target
|
50%
|
|
|
103% of
Target
|
75%
|
|
Maximum
|
105% of
Target
|
100%
|
The proportions vesting between the above vesting levels will be
calculated on a straight-line basis.
Pipeline Progress measure
The Pipeline Progress measure, introduced in 2020, reflects our
emphasis on Innovation and seeks to reward acceleration and
strengthening of the pipeline. The measure is based on two equally
weighted elements of our key assets or
indications:
|
Proportion of award
|
Pipeline Progress - Sub-measure
|
|
10%
|
Pivotal trial starts, which focus mainly on phase III
registrational trial starts, but may also include phase II starts
(for example, in oncology)
|
|
10%
|
Major regulatory approval milestones
|
Points will be allocated to the successful assets in each
sub-measure based upon their forecast commercial value (peak year
sales) at the end of the performance period.
The points vesting scales for these sub-measures of the 2023 award
will be published as part of the 2022 Annual Report.
Due to commercial sensitivity, the Remuneration Committee remains
of the view that the Pipeline Progress measure targets cannot be
published at the time of grant. At the end of the performance
period we will provide full disclosure of what has been achieved,
in terms of both milestones and aggregate points, along with a
narrative commentary on performance.
ESG: Environment measure
An ESG Environment measure was introduced, based upon our Trust
priority and goal of having a Nature Net Positive and Climate Net
Zero impact by 2030, details of which are provided on our
website. The ESG
Environment measure includes six key performance indicators (KPIs),
three towards our Climate ambitions and three towards our Nature
ambitions. To achieve 75% vesting, all six measures must have
met their 2025 targets. To achieve 100% vesting, two of the
six measures, at least one in Climate and one in Nature, must have
exceeded their 2025 targets.
Notes
1.
To the extent that each element of a conditional award does
not vest at the end of the three-year performance period, it will
lapse.
2.
The PDMRs in the transaction notifications below were each
granted a conditional award under the terms of the GlaxoSmithKline
2017 Performance Share Plan. Awards granted are of Ordinary
Shares or ADSs.
3.
Dividends will accrue on the conditional award of Ordinary
Shares or ADSs during the performance period but will only vest to
the extent that the awards themselves vest at the end of the
performance period. These dividends are not included in the figures
below.
4.
For Executive Directors, the award is subject to an
additional vesting period of two years (the 'Holding Period') from
the normal vesting date, i.e. five years in total. During the
additional Holding Period, the relevant Ordinary Shares or ADSs
would only be forfeited in the event that the Executive Director
was terminated for cause, and the Ordinary Shares or ADSs will
continue to carry rights to dividend
equivalents.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms E Walmsley
|
|||
|
b)
|
Position/status
|
Chief
Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
|
501,927
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms D Conrad
|
|||
|
b)
|
Position/status
|
Chief
People Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of notional Ordinary Shares under the Company's
2017 Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010.
|
111,052
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr J Ford
|
|||
|
b)
|
Position/status
|
SVP and
Group General Counsel, Legal and Compliance
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
..
|
172,924
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms S Jackson
|
|||
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
..
|
72,695
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr D Jackson
|
|||
|
b)
|
Position/status
|
PCA of
Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
..
|
5,570
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr L Miels
|
|||
|
b)
|
Position/status
|
Chief
Commercial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
|
265,822
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms S Ramakrishnan
|
|||
|
b)
|
Position/status
|
Chief
Digital and Technology Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of ADSs under the Company's 2017 Performance
Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$36.32
|
64,427
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr D Redfern
|
|||
|
b)
|
Position/status
|
President
Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
|
185,317
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr R Simard
|
|||
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
|
187,475
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr P Thomson
|
|||
|
b)
|
Position/status
|
President,
Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
|
85,471
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms D Waterhouse
|
|||
|
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
|
176,282
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr T Wood
|
|||
|
b)
|
Position/status
|
Chief
Scientific Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
|
237,841
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Ms V Whyte
|
|||
|
b)
|
Position/status
|
Company
Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£15.010
..
|
11,800
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2023-02-09
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
14, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|